secwatch.observer — SEC 8-K summary
======================================

Issuer:     Skye Bioscience, Inc. (SKYE)
CIK:        0001516551
Form:       8-K
Filed at:   2021-10-06T23:59:59+00:00
Accession:  0001516551-21-000015
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Skye Bioscience appoints Kaitlyn Arsenault as CFO, replacing interim Principal Accounting Officer
--------------------------------------------------------------------------------

- Punit Dhillon resigned as interim Principal Accounting Officer effective Oct 4, 2021; Kaitlyn Arsenault appointed CFO immediately.
- Arsenault receives options for 1.6M shares at $0.09; 10% vest immediately, remainder over 4 years semi-annually.
- Annual base salary $300k with discretionary bonus up to 35% of base; severance of 6 months' salary if terminated not for cause.
- Arsenault has 14+ years experience in life science accounting, previously consultant to Skye for 6 years and Assurance Manager at Friedman LLP.
- Skye is a biopharma developing cannabinoid-derived molecules for unmet medical needs; CFO appointment supports clinical program advancement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1516551/000151655121000015/0001516551-21-000015-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1516551/000151655121000015/skye-20211005.htm
  HTML page:      https://secwatch.observer/filing/0001516551-21-000015

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer